ARTICLE | Finance

Anchors Aweigh

Anchor Therapeutics expects pepducins to reach clinic with new B round

August 30, 2010 7:00 AM UTC

The first $10 million close of a planned $15-$20 million series B round is expected to get Anchor Therapeutics Inc. to at least one, or possibly two, INDs.

Anchor (formerly Ascent Therapeutics Inc.) is developing pepducins. These cell-penetrating lipopeptides act as GPCR modulators inside the cell, rather than externally on the cell surface (see BioCentury, Jan. 5, 2009)...